Skip to main content
SpringerLink
Log in

Gout Flare Burden, Diagnosis, and Management: Navigating Care in Older Patients with Comorbidity

  • Therapy in Practice
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Gout is the most common form of inflammatory arthritis, and its incidence is highest in middle-aged and older patients. Adding to the diagnostic complexity, up to 50% of patients aged > 65 years present atypically, with subacute oligo- or polyarticular flares. Comorbidity and polypharmacy, common in older populations, affect real-world treatment decisions in gout management, and no specific guidelines are available to address these issues in these at-risk groups. Despite the growing public health burden posed by gout, suboptimal management has led to increased morbidity and substantial healthcare utilization and cost burden, as reflected by an increased incidence of emergency department visits and hospitalizations in recent years. Colchicine, nonsteroidal anti-inflammatory drugs, or glucocorticoids (oral, intraarticular, or intramuscular) should be considered as first-line agents for gout flare management. Urate-lowering therapy, with the goal of lowering and maintaining serum urate concentrations at < 6 mg/dL (< 360 μmol/L), is recommended to achieve optimal outcomes, including regression of tophi, reduction (or elimination) of flares, and reductions in total urate burden. In this review, we summarize the current burden posed by gout and discuss best practices in its diagnosis and management, focusing on best practices in the context of gout flare in older patients with comorbid conditions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Janssen CA, Jansen TLTA, Oude Voshaar MAH, Vonkeman HE, van de Laar MAFJ. Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients. Rheumatol Int. 2017;37:1435–40.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Roddy E, Doherty M. Epidemiology of gout. Arthritis Res Ther. 2010;12:223.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Doghramji PP, Fermer S, Wood R, Morlock R, Baumgartner S. Management of gout in the real world: current practice versus guideline recommendations. Postgrad Med. 2016;128:106–14.

    Article  PubMed  Google Scholar 

  4. Smith E, Hoy D, Cross M, Merriman TR, Vos T, Buchbinder R, et al. The global burden of gout: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis. 2014;73:1470.

    Article  PubMed  Google Scholar 

  5. Wertheimer A, Morlock R, Becker MA. A revised estimate of the burden of illness of gout. Curr Ther Res. 2013;75:1–4.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Flores NM, Nuevo J, Klein AB, Baumgartner S, Morlock R. The economic burden of uncontrolled gout: how controlling gout reduces cost. J Med Econ. 2019:22:1–6.

    Article  PubMed  Google Scholar 

  7. Juraschek SP, Kovell LC, Miller ER 3rd, Gelber AC. Gout, urate-lowering therapy, and uric acid levels among adults in the United States. Arthritis Care Res. 2015;67:588–92.

    Article  CAS  Google Scholar 

  8. Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK. Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the National Health and Nutrition Examination Survey, 2007–2016. Arthritis Rheumatol (Hoboken, NJ). 2019;71:991–9.

    Article  Google Scholar 

  9. Riedel AA, Nelson M, Wallace K, Joseph-Ridge N, Cleary M, Fam AG. Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting. J Clin Rheumatol. 2004;10:308–14.

    Article  PubMed  Google Scholar 

  10. Helget LN, England BR, Roul P, Sayles H, Petro AD, Michaud K, et al. The incidence, prevalence, and burden of gout in the Veterans Health Administration. Arthritis Care Res. 2020. https://doi.org/10.1002/acr.24339.

  11. Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005. Ann Rheum Dis. 2008;67:960–6.

    Article  CAS  PubMed  Google Scholar 

  12. Bolzetta F, Veronese N, Manzato E, Sergi G. Chronic gout in the elderly. Aging Clin Exp Res. 2013;25:129–37.

    Article  PubMed  Google Scholar 

  13. Cannella AC, Mikuls TR. Understanding treatments for gout. Am J Manag Care. 2005;11:S451–8.

    PubMed  Google Scholar 

  14. Major TJ, Topless RK, Dalbeth N, Merriman TR. Evaluation of the diet wide contribution to serum urate levels: meta-analysis of population based cohorts. BMJ. 2018;363:k3951.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med. 2004;350:1093–103.

    Article  CAS  PubMed  Google Scholar 

  16. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Alcohol intake and risk of incident gout in men: a prospective study. Lancet. 2004;363:1277–81.

    Article  PubMed  Google Scholar 

  17. Wu EQ, Patel PA, Yu AP, Mody RR, Cahill KE, Tang J, et al. Disease-related and all-cause health care costs of elderly patients with gout. J Manag Care Pharm. 2008;14:164–75.

    PubMed  Google Scholar 

  18. Singh JA, Yu S. Time trends, predictors, and outcome of emergency department use for gout: a nationwide US study. J Rheumatol. 2016;43:1581–8.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Bulbin D, Denio AE, Berger A, Brown J, Maynard C, Sharma T, et al. Improved gout outcomes in primary care using a novel disease management program: a pilot study. Arthritis Care Res (Hoboken). 2018;70:1679–85.

    Article  CAS  Google Scholar 

  20. Singh JA, Yu S. Gout-related inpatient utilization: a study of predictors of outcomes and time trends. Arthritis Res Ther. 2016;18:57.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Lim SY, Lu N, Oza A, Fisher M, Rai SK, Menendez ME, et al. Trends in Gout and Rheumatoid Arthritis Hospitalizations in the United States, 1993–2011. JAMA. 2016;315:2345–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Han G, Michaud K, Yu F, Watanabe-Galloway S, Mikuls TR. Increasing public health burden of arthritis and other rheumatic conditions and comorbidity: results from a Statewide Health Surveillance System, 2007–2012. Arthritis Care Res. 2016;68:1417–27.

    Article  Google Scholar 

  23. Park H, Rascati KL, Prasla K, McBayne T. Evaluation of health care costs and utilization patterns for patients with gout. Clin Ther. 2012;34:640–52.

    Article  PubMed  Google Scholar 

  24. Rai SK, Burns LC, De Vera MA, Haji A, Giustini D, Choi HK. The economic burden of gout: a systematic review. Semin Arthritis Rheum. 2015;45:75–80.

    Article  PubMed  Google Scholar 

  25. Janssens HJ, Arts PG, Schalk BW, Biermans MC. Gout and rheumatoid arthritis, both to keep in mind in cardiovascular risk management: a primary care retrospective cohort study. Joint Bone Spine. 2017;84:59–64.

    Article  PubMed  Google Scholar 

  26. Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Schumacher HR, Saag KG. Gout epidemiology: results from the UK General Practice Research Database, 1990–1999. Ann Rheum Dis. 2005;64:267–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Stokes T, Azam M, Noble FD. Multimorbidity in Māori and Pacific patients: cross-sectional study in a Dunedin general practice. J Prim Health Care. 2018;10:39–43.

    Article  PubMed  Google Scholar 

  28. Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med. 2017;15:123.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Vargas-Santos A, Neogi T, da Rocha C-PG, Kapetanovic MC, Turkiewicz A. Cause-specific mortality in gout: novel findings of elevated risk of non-cardiovascular-related deaths. Arthritis Rheumatol (Hoboken, NJ). 2019;71:1935–42.

    Article  Google Scholar 

  30. Stewart S, Guillen AG, Taylor WJ, Gaffo A, Slark J, Gott M, et al. The experience of a gout flare: a meta-synthesis of qualitative studies. Semin Arthritis Rheum. 2020;50:805–11.

    Article  PubMed  Google Scholar 

  31. Garcia-Guillen A, Stewart S, Su I, Taylor WJ, Gaffo AL, Gott M, et al. Gout flare severity from the patient perspective: a qualitative interview study. Arthritis Care Res (Hoboken). 2020. https://doi.org/10.1002/acr.24475.

  32. Bardin T, Richette P. Definition of hyperuricemia and gouty conditions. Curr Opin Rheumatol. 2014;26:186–91.

    Article  CAS  PubMed  Google Scholar 

  33. Dalbeth N, Stamp L. Hyperuricaemia and gout: time for a new staging system? Ann Rheum Dis. 2014;73:1598.

    Article  PubMed  Google Scholar 

  34. FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020;72:744–60.

    Article  Google Scholar 

  35. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007–2008. Am J Med. 2012;125:679-687.e1.

    Article  PubMed  Google Scholar 

  36. Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2015;74:1789–98.

    Article  CAS  Google Scholar 

  37. Choi HK, Niu J, Neogi T, Chen CA, Chaisson C, Hunter D, et al. Nocturnal risk of gout attacks. Arthritis Rheumatol (Hoboken, NJ). 2015;67:555–62.

    Article  Google Scholar 

  38. Stamp LK, Jordan S. The challenges of gout management in the elderly. Drugs Aging. 2011;28:591–603.

    Article  CAS  PubMed  Google Scholar 

  39. De Leonardis F, Govoni M, Colina M, Bruschi M, Trotta F. Elderly-onset gout: a review. Rheumatol Int. 2007;28:1–6.

    Article  PubMed  Google Scholar 

  40. Reginato AJ, Schumacher HR Jr. Crystal-associated arthropathies. Clin Geriatr Med. 1988;4:295–322.

    Article  CAS  PubMed  Google Scholar 

  41. Margaretten ME, Kohlwes J, Moore D, Bent S. Does this adult patient have septic arthritis? JAMA. 2007;297:1478–88.

    Article  CAS  PubMed  Google Scholar 

  42. Abhishek A. Managing gout flares in the elderly: practical considerations. Drugs Aging. 2017;34:873–80.

    Article  CAS  PubMed  Google Scholar 

  43. Schlee S, Bollheimer LC, Bertsch T, Sieber CC, Härle P. Crystal arthritides—gout and calcium pyrophosphate arthritis: part 2: clinical features, diagnosis and differential diagnostics. Z Gerontol Geriatr. 2018;51:579–84.

    Article  CAS  PubMed  Google Scholar 

  44. Pascual E, Batlle-Gualda E, Martínez A, Rosas J, Vela P. Synovial fluid analysis for diagnosis of intercritical gout. Ann Intern Med. 1999;131:756–9.

    Article  CAS  PubMed  Google Scholar 

  45. Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet. 2016;388:2039–52.

    Article  CAS  PubMed  Google Scholar 

  46. Lawry GV 2nd, Fan PT, Bluestone R. Polyarticular versus monoarticular gout: a prospective, comparative analysis of clinical features. Medicine (Baltimore). 1988;67:335–43.

    Article  Google Scholar 

  47. Petersel D, Schlesinger N. Treatment of acute gout in hospitalized patients. J Rheumatol. 2007;34:1566–8.

    PubMed  Google Scholar 

  48. Logan JA, Morrison E, McGill PE. Serum uric acid in acute gout. Ann Rheum Dis. 1997;56:696–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Schlesinger N. Diagnosis of gout: clinical, laboratory, and radiologic findings. Am J Manag Care. 2005;11:S443–8.

    PubMed  Google Scholar 

  50. Schlesinger N, Norquist JM, Watson DJ. Serum urate during acute gout. J Rheumatol. 2009;36:1287–9.

    Article  CAS  PubMed  Google Scholar 

  51. Upadhyay N, Saifuddin A. The radiographic and MRI features of gout referred as suspected soft tissue sarcoma: a review of the literature and findings from 27 cases. Skelet Radiol. 2015;44:467–76.

    Article  Google Scholar 

  52. Omoumi P, Zufferey P, Malghem J, So A. Imaging in gout and other crystal-related arthropathies. Rheum Dis Clin N Am. 2016;42:621–44.

    Article  Google Scholar 

  53. Thiele RG. Role of ultrasound and other advanced imaging in the diagnosis and management of gout. Curr Rheumatol Rep. 2011;13:146–53.

    Article  PubMed  Google Scholar 

  54. Glazebrook KN, Guimarães LS, Murthy NS, Black DF, Bongartz T, Manek NJ, et al. Identification of intraarticular and periarticular uric acid crystals with dual-energy CT: initial evaluation. Radiology. 2011;261:516–24.

    Article  PubMed  Google Scholar 

  55. Nicolaou S, Yong-Hing CJ, Galea-Soler S, Hou DJ, Louis L, Munk P. Dual-energy CT as a potential new diagnostic tool in the management of gout in the acute setting. AJR Am J Roentgenol. 2010;194:1072–8.

    Article  PubMed  Google Scholar 

  56. Carroll M, Dalbeth N, Allen B, Stewart S, House T, Boocock M, et al. Ultrasound characteristics of the achilles tendon in tophaceous gout: a comparison with age- and sex-matched controls. J Rheumatol. 2017;44:1487–92.

    Article  PubMed  Google Scholar 

  57. Kienhorst LBE, Janssens HJEM, Fransen J, Janssen M. The validation of a diagnostic rule for gout without joint fluid analysis: a prospective study. Rheumatology (Oxford). 2015;54:609–14.

    Article  Google Scholar 

  58. Janssens HJEM, Fransen J, van de Lisdonk EH, van Riel PLCM, van Weel C, Janssen M. A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis. Arch Intern Med. 2010;170:1120–6.

    Article  PubMed  Google Scholar 

  59. Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76:29.

    Article  CAS  PubMed  Google Scholar 

  60. Neogi T. Clinical practice. Gout. N Engl J Med. 2011;364:443–52.

    Article  CAS  PubMed  Google Scholar 

  61. Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62:1060–8.

    Article  CAS  PubMed  Google Scholar 

  62. Terkeltaub RA, Furst DE, DiGiacinto JL, Kook KA, Davis MW. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum. 2011;63:2226–37.

    Article  CAS  PubMed  Google Scholar 

  63. Vargas-Santos A, Neogi T. Management of gout and hyperuricemia in CKD. Am J Kidney Dis. 2017;70:422–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Billy CA, Lim RT, Ruospo M, Palmer SC, Strippoli GFM. Corticosteroid or nonsteroidal antiinflammatory drugs for the treatment of acute gout: a systematic review of randomized controlled trials. J Rheumatol. 2018;45:128–36.

    Article  CAS  PubMed  Google Scholar 

  65. Janssens HJ, Janssen M, van de Lisdonk EH, van Riel PL, van Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet. 2008;371:1854–60.

    Article  CAS  PubMed  Google Scholar 

  66. Man CY, Cheung IT, Cameron PA, Rainer TH. Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial. Ann Emerg Med. 2007;49:670–7.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Wechalekar MD, Vinik O, Schlesinger N, Buchbinder R. Intra-articular glucocorticoids for acute gout. Cochrane Database Syst Rev. 2013;(4):CD009920.

  68. Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012;64:1447–61.

    Article  CAS  Google Scholar 

  69. Singh H, Torralba KD. Therapeutic challenges in the management of gout in the elderly. Geriatrics. 2008;63(13–8):20.

    Google Scholar 

  70. Daoussis D, Antonopoulos I, Yiannopoulos G, Andonopoulos AP. ACTH as first line treatment for acute gout in 181 hospitalized patients. Jt Bone Spine. 2013;80:291–4.

    Article  CAS  Google Scholar 

  71. Daoussis D, Bogdanos DP, Dimitroulas T, Sakkas L, Andonopoulos AP. Adrenocorticotropic hormone: an effective “natural” biologic therapy for acute gout? Rheumatol Int. 2020;40:1941–7.

    Article  PubMed  Google Scholar 

  72. Chen K, Fields T, Mancuso CA, Bass AR, Vasanth L. Anakinra’s efficacy is variable in refractory gout: report of ten cases. Semin Arthritis Rheum. 2010;40:210–4.

    Article  CAS  PubMed  Google Scholar 

  73. So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther. 2007;9:R28.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Saag KG, Khanna PP, Keenan RT, Ohlman S, Osterling Koskinen L, Sparve E, et al. A randomized, phase 2 study evaluating the efficacy and safety of anakinra in the treatment of gout flares. Arthritis Rheumatol. 2021. https://doi.org/10.1002/art.41699.

  75. Schlesinger N, Detry MA, Holland BK, Baker DG, Beutler AM, Rull M, et al. Local ice therapy during bouts of acute gouty arthritis. J Rheumatol. 2002;29:331.

    PubMed  Google Scholar 

  76. Dalal DS, Mbuyi N, Shah I, Reinert S, Hilliard R, Reginato A. Prescription opioid use among patients with acute gout discharged from the emergency department. Arthritis Care Res (Hoboken). 2020;72:1163–8.

    Article  Google Scholar 

  77. Singh JA, Cleveland JD. Time trends in opioid use disorder hospitalizations in gout, rheumatoid arthritis, fibromyalgia, osteoarthritis, and low back pain. J Rheumatol. 2021;48:775–84.

    Article  PubMed  Google Scholar 

  78. Hui M, Carr A, Cameron S, Davenport G, Doherty M, Forrester H, et al. The British Society for rheumatology guideline for the management of gout. Rheumatology (Oxford). 2017;56:e1–20.

    Article  CAS  Google Scholar 

  79. Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 2002;47:356–60.

    Article  CAS  PubMed  Google Scholar 

  80. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004;51:321–5.

    Article  CAS  PubMed  Google Scholar 

  81. Li-Yu J, Clayburne G, Sieck M, Beutler A, Rull M, Eisner E, et al. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol. 2001;28:577–80.

    CAS  PubMed  Google Scholar 

  82. Hughes JC, Wallace JL, Bryant CL, Salvig BE, Fourakre TN, Stone WJ. Monitoring of urate-lowering therapy among us veterans following the 2012 American college of rheumatology guidelines for management of gout. Ann Pharmacother. 2017;51:301–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology, Department of Internal Medicine, University of Nebraska Medical Center, 986270 Nebraska Medical Center, Omaha, NE, 68198-6270, USA

    Mukund Kumar & Ted R. Mikuls

  2. Medicine and Research, VA Nebraska-Western Iowa Health Care System, Omaha, NE, USA

    Mukund Kumar & Ted R. Mikuls

  3. Division of Geriatrics, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA

    Natalie Manley

Authors
  1. Mukund Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Natalie Manley
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ted R. Mikuls
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ted R. Mikuls.

Ethics declarations

Funding

No sources of funding were used to conduct this study or prepare this manuscript.

Conflict of interest

TRM has received prior research funding and has served as a consultant for Horizon Therapeutics. MK and NM have no conflicts of interest that are directly relevant to the content of this article.

Availability of data and materials

Not applicable.

Ethics approval

Not applicable.

Consent

Not applicable.

Author contributions

All authors were involved in the literature search, the initial drafting of the manuscript, and the revision and approval of the final manuscript.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kumar, M., Manley, N. & Mikuls, T.R. Gout Flare Burden, Diagnosis, and Management: Navigating Care in Older Patients with Comorbidity. Drugs Aging 38, 545–557 (2021). https://doi.org/10.1007/s40266-021-00866-2

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-021-00866-2

Search

Navigation